Humacyte Inc (HUMA) Stock Price, Quote & News

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 313 9633

Website: www.humacyte.com

Address:

2525 East North Carolina Highway 54, Durham, United States

audiobookprisonstories May. 29 at 4:02 PM

$HUMA IF SHORTS COVER ROCKETS 🚀 INTO JUNE 11 DATA

0 · Reply

HappyEndings May. 29 at 3:44 PM

$HUMA gotta get the fuck out of that $1.31.

0 · Reply

audiobookprisonstories May. 29 at 2:57 PM

$SOXS MADE ANOTHER APPROX 10K SCALPING SOXS AND ADDED TO $LABD SWING STILL VERY LONG $HUMA

0 · Reply

Wolf1971 May. 29 at 2:27 PM

$HUMA voo7 standard of care

0 · Reply

Runmaster83 May. 29 at 2:24 PM

$HUMA Shorts trying hard….

0 · Reply

Timerider May. 29 at 1:58 PM

$HUMA Just Retested 200 day 1.245. SEND IT

0 · Reply

Inspire2023 May. 29 at 12:41 PM

$HUMA $SOFI $NOW $NOWL

1 · Reply

malphius May. 29 at 12:39 PM

$HUMA Let's close strong at $1.50 today.

0 · Reply

Michael_Krombopulos May. 29 at 12:36 PM

$HUMA don’t fall for it. Has to finance and dillute again and financial engineering for the float size. ER sold down because the jig is up, they are going to cause hype and follow the trial news with an offering and split. Historically she has not let this ever run more than half a day before deciding to do something to ruin it .. watch . Sell the news event will be a sell into the news event

2 · Reply

Macroghost May. 29 at 11:44 AM

$IBRX Technical Analysis + Humacyte ($HUMA) Update 3 reasons to buy Huma and 1 reason not to (TLDR: wait for better prices) https://youtu.be/_sD1fNxot4Q

0 · Reply

Humacyte announces presentation at VASA meeting on self-repair ATEV

May 26, 2026, 8:00 AM EDT - 3 days ago

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

2026-05-20T12:14:56.000Z - 9 days ago

Humacyte reports Symvess under contract with Strategic Acquisition Center of VA

May 20, 2026, 8:00 AM EDT - 9 days ago

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

2026-05-14T15:08:47.000Z - 15 days ago

Humacyte price target raised to $1.50 from $1 at TD Cowen

May 13, 2026, 10:09 AM EDT - 16 days ago

Humacyte Q1 Earnings Call Highlights

2026-05-13T13:00:50.000Z - 16 days ago

Humacyte reports Q1 EPS (9c), consensus (12c)

May 13, 2026, 8:00 AM EDT - 16 days ago

Humacyte Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 16 days ago

Humacyte Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 16 days ago

Humacyte Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 16 days ago

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

2026-05-12T15:32:56.000Z - 17 days ago

Humacyte names Todd Rasmussen chief surgical officer

May 12, 2026, 8:00 AM EDT - 17 days ago

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

May 8, 2026, 6:00 PM EDT - 20 days ago

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

May 8, 2026, 8:00 AM EDT - 21 days ago

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

Humacyte Transcript: KOL event

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

Humacyte Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

2026-04-24T12:33:04.000Z - 5 weeks ago

Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact

FMS

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Apr 22, 2026, 8:00 AM EDT - 5 weeks ago

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

2026-04-21T13:26:28.000Z - 5 weeks ago

Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Humacyte Proxy statement: Proxy filing

Apr 9, 2026, 3:50 PM EDT - 7 weeks ago

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-04-08T09:30:25.000Z - 7 weeks ago

Humacyte price target lowered to $1.50 from $3.50 at Barclays

2026-03-31T13:30:42.000Z - 2 months ago

Humacyte downgraded to Speculative Buy from Buy at Benchmark

2026-03-30T12:05:04.000Z - 2 months ago

Humacyte price target lowered to $1 from $3.50 at TD Cowen

2026-03-30T11:58:53.000Z - 2 months ago

Humacyte price target lowered to $1 from $3 at Piper Sandler

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Humacyte Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Humacyte Annual report: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Humacyte Earnings release: Q4 2025

2026-03-27T11:22:11.000Z - 2 months ago

Humacyte reports Q4 EPS (13c), consensus (14c)

Mar 27, 2026, 7:00 AM EDT - 2 months ago

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 26, 2026, 8:00 AM EDT - 2 months ago

Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

2026-03-19T12:36:23.000Z - 2 months ago

Humacyte prices $20M registered direct offering

2026-03-19T12:36:11.000Z - 2 months ago

Humacyte receives Symvess purchase commitment

Mar 19, 2026, 8:30 AM EDT - 2 months ago

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Mar 17, 2026, 8:00 AM EDT - 2 months ago

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Mar 10, 2026, 1:00 PM EDT - 2 months ago

Humacyte Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 4, 2026, 10:30 AM EST - 3 months ago

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 3 months ago

Humacyte To Participate in Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 3 months ago

Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

Feb 9, 2026, 8:00 AM EST - 3 months ago

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Jan 8, 2026, 8:00 AM EST - 5 months ago

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Jan 5, 2026, 8:00 AM EST - 5 months ago

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Dec 22, 2025, 8:00 AM EST - 5 months ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Dec 16, 2025, 8:00 AM EST - 5 months ago

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Nov 20, 2025, 8:00 AM EST - 6 months ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 13, 2025, 8:00 AM EST - 7 months ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 12, 2025, 8:00 AM EST - 7 months ago

Humacyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Humacyte Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Humacyte Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 7 months ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 7, 2025, 9:00 AM EDT - 8 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Sep 29, 2025, 8:00 AM EDT - 8 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 18, 2025, 7:00 AM EDT - 9 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 15, 2025, 7:00 AM EDT - 9 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 12, 2025, 8:00 AM EDT - 9 months ago

Humacyte Registration statement: Registration Filing

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Humacyte Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Humacyte Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Humacyte Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jul 23, 2025, 8:00 AM EDT - 11 months ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

May 20, 2025, 12:30 PM EDT - 1 year ago

Humacyte Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 4:05 PM EDT - 1 year ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings release: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 8:00 AM EDT - 1 year ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Annual report: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings release: Q4 2024

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 25, 2025, 8:35 PM EDT - 1 year ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 6, 2025, 12:00 PM EST - 1 year ago

Humacyte Transcript: Investor Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Trestle Bio Announces Research Collaboration with Humacyte

audiobookprisonstories May. 29 at 4:02 PM

$HUMA IF SHORTS COVER ROCKETS 🚀 INTO JUNE 11 DATA

0 · Reply

HappyEndings May. 29 at 3:44 PM

$HUMA gotta get the fuck out of that $1.31.

0 · Reply

audiobookprisonstories May. 29 at 2:57 PM

$SOXS MADE ANOTHER APPROX 10K SCALPING SOXS AND ADDED TO $LABD SWING STILL VERY LONG $HUMA

0 · Reply

Wolf1971 May. 29 at 2:27 PM

$HUMA voo7 standard of care

0 · Reply

Runmaster83 May. 29 at 2:24 PM

$HUMA Shorts trying hard….

0 · Reply

Timerider May. 29 at 1:58 PM

$HUMA Just Retested 200 day 1.245. SEND IT

0 · Reply

Inspire2023 May. 29 at 12:41 PM

$HUMA $SOFI $NOW $NOWL

1 · Reply

malphius May. 29 at 12:39 PM

$HUMA Let's close strong at $1.50 today.

0 · Reply

Michael_Krombopulos May. 29 at 12:36 PM

2 · Reply

Macroghost May. 29 at 11:44 AM

$IBRX Technical Analysis + Humacyte ($HUMA) Update 3 reasons to buy Huma and 1 reason not to (TLDR: wait for better prices) https://youtu.be/_sD1fNxot4Q

0 · Reply

Revrasmilitia May. 29 at 2:29 AM

$HUMA Averaged down over the past year and now Green!

2 · Reply

MeetyaMaker May. 29 at 2:09 AM

$HUMA looks like it'll be at 3ish leading up to june 11th.

0 · Reply

SteelerJon May. 29 at 1:33 AM

$HUMA Great day😎👊🏻

0 · Reply

Runmaster83 May. 29 at 12:10 AM

$HUMA Anyone have a chart to share?! Did we close above 200/Day?! Guesses where we go over next two weeks?

1 · Reply

Timerider May. 28 at 11:49 PM

$HUMA 11% gain on 162% volume, hedgefunds notice this in the weeds to max themselves. Les Goh and Wen Moon jetting to Fiji to chillax

0 · Reply

HaveYouSeenMySocks May. 28 at 11:19 PM

$HUMA wheres the next resistance? Above $2?

1 · Reply

Timerider May. 28 at 10:09 PM

$HUMA Karen Sebelius knew if she bot 1M shares at .60 there would be scrutiny. A mete 56k at .88 was a slow play ace-king

1 · Reply

Runmaster83 May. 28 at 10:07 PM

$HUMA Not great prognostication skills

0 · Reply

rekked87 May. 28 at 9:21 PM

$HUMA back down tomorrow

3 · Reply

forgottenchuck May. 28 at 8:57 PM

$HUMA

1 · Reply

forgottenchuck May. 28 at 8:53 PM

$HUMA the TODD RASUMUSSEN effect. the institutions know how big of a hire TODD was to humacyte

0 · Reply

Snikkle May. 28 at 8:03 PM

$HUMA Pretty amazing considering there hasn’t been significant short covering yet

0 · Reply

Market Cap	255.32M
Revenue (ttm)	2.04M
Net Income (ttm)	-40.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,001.47%
Debt to Equity Ratio	3.09

Volume	11,287,000
Avg Vol	7,937,976
Day's Range	N/A - N/A
Shares Out	222.02M
Stochastic %K	96%
Beta	2.31
Analysts	Strong Sell
Price Target	$5.00